Behold.ai receives approval for red dot® imaging recognition algorithm.
London-based Behold.ai received 510(k) clearance from the U.S. Food & Drug Administration this week for its automatic diagnosis tool for pneumothorax.
Referring to the tool as an “instant triage,” the company said its red dot® algorithm alerts radiologists as soon as it captures a pneumothorax on a X-ray image.
According to a company statement, the tool not only saves reading time, but it can also help reduce the cost of diagnosis when used in conjunction with other products.
“FDA clearance is not just about safety, but also about efficacy,” said Behold.ai Chief Executive Officer Simon Rasalingham, in a press statement. “We believe our technology can make a big difference to patient safety, the delivery of care and cost-savings to the system.”
Based on company information, customers will be charged on a per exam basis, and red dot® will be commercially available in the United States later this year.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.